Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99Tc-MDP for rheumatic immune disease with osteoporosis or low bone mass
ChiCTR2100052383Phase 4Not yet recruiting
- Sponsor
- Leshan People's Hospital
- Start
- Jan 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of technetium-99m-methylene diphosphonate in osteoporosis, osteopenia and autoimmune and inflammatory rheumatic disease (AIIRD), sponsored by Leshan People's Hospital. Primary endpoints: Total procollagen type I amino-terminal propeptide, β-collagen specific sequence and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
technetium-99m-methylene diphosphonate
03
Conditions
osteoporosisosteopeniaautoimmune and inflammatory rheumatic disease (AIIRD)
Beyond the preview
Go deeper on ChiCTR2100052383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052383.